Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cubist Touts Activity Of Its Broad-Spectrum Antibiotic Candidate Against High Value Gram-Negative Targets

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Cubist Pharmaceuticals laid out the regulatory plan for its novel broad-spectrum cephalosporin/tazobactam combination antibiotic CXA-201 during an R&D day Sept. 20, disclosing plans to go ahead with development of the drug in hospital-acquired and ventilator-associated pneumonia

You may also be interested in...



Novel Antibiotics At ICAAC Spur Optimism On Resistance Front

While short-term prospects are dim for new antibiotics to treat multi-drug-resistant pathogens – Gram-negative bacteria in particular – research presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy indicates a handful of novel compounds could be ready for prime time in as few as four or five years.

Novel Antibiotics At ICAAC Spur Optimism On Resistance Front

While short-term prospects are dim for new antibiotics to treat multi-drug-resistant pathogens – Gram-negative bacteria in particular – research presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy indicates a handful of novel compounds could be ready for prime time in as few as four or five years.

Antibiotic Development: Where Wall Street Guidance Is Watching FDA Guidances

FDA's effort to create a clearer path for antibiotic development has produced a series of new guidance documents. Those guidances are making some products in development look well-positioned for regulatory review, and rekindling the interest on Wall Street in specialty antibiotic firms. This article first appeared in the May 2011 issue of The RPM Report.

Related Content

Topics

UsernamePublicRestriction

Register

PS004548

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel